Pharma manufacturers/companies spend a lot of money on rebates every year to ensure that their drugs get favourable formulary access through PBMs. This has not been the case with our clients!
Our Payer Contracting Models help pharma companies find optimal access leading to an increase in gross profits instead of the best formulary access (which often demands high rebates). Pharmaceutical companies that use our Payer contracting strategies see an increase in their investment returns by 10% to 25%.
